Nautilus Biotechnology, Inc. (NAUT) NASDAQ
2.33
+0.04(+1.75%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.33
+0.04(+1.75%)
Currency In USD
| Previous Close | 2.29 |
| Open | 2.26 |
| Day High | 2.38 |
| Day Low | 2.21 |
| 52-Week High | 3.08 |
| 52-Week Low | 0.62 |
| Volume | 142,437 |
| Average Volume | 215,793 |
| Market Cap | 294.89M |
| PE | -4.96 |
| EPS | -0.47 |
| Moving Average 50 Days | 2.24 |
| Moving Average 200 Days | 1.39 |
| Change | 0.04 |
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (N
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomic
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual H